Sanofi disinvests Brazilian generics unit Medley to EMS in USD500M deal

BRAZIL—Sanofi has agreed to sell its Medley generics unit in Brazil to leading local drugmaker EMS, marking another significant step in the pharmaceutical giant’s ongoing transformation.

The French company has spent the past year aggressively reshaping its portfolio by divesting consumer-focused assets and reinvesting those proceeds into innovative drug development and strategic acquisitions, with this latest transaction reinforcing that strategic direction.

The sale requires approval from Brazilian regulators, but EMS expressed confidence in the outcome.

According to Reuters, the deal is valued at over USD500 million, a substantial acquisition that positions EMS to strengthen its presence in Brazil’s competitive generics market.

The transaction reflects the growing consolidation trend in that segment, where scale and operational efficiency determine competitive advantage.

Growth plans and employment protection

Rather than consolidating operations through plant closures, EMS intends to retain Medley’s existing facilities and invest in future expansion.

Marcus Sanchez, a vice president at EMS, stated that the combined entity plans to expand its offerings in the Brazilian generics segment and accelerate development of new, innovative products.

This growth-oriented approach suggests that EMS views Medley as a foundation for regional expansion rather than a target for cost-cutting restructuring.

Sanofi’s broader strategic initiative

Sanofi’s acquisition of Medley in 2009 for 500 million euros (USD 545 million) came at a time when Medley ranked as Brazil’s third-largest pharmaceutical company and its leading generics manufacturer, with more than 100 products in its portfolio.

Since then, the unit remained a solid performer but increasingly represented a non-core asset as Sanofi shifted focus toward higher-margin specialty pharmaceuticals.

The Medley sale follows Sanofi’s blockbuster divestiture of Opella, its consumer health division, which sold for 10 billion euros (USD 10.9 billion) in 2023.

Following that landmark transaction, Sanofi embarked on an aggressive acquisition spree, acquiring biotech firms Vigil Neuroscience, Blueprint Medicines, and Dynavax to bolster its innovation pipeline.

This dealmaking activity demonstrates a company committed to transforming itself from a diversified pharmaceutical conglomerate into a focused innovator.

Earlier portfolio actions and leadership transition

Beyond last year’s major transactions, Sanofi has pursued selective divestitures of established and consumer health medicines earlier this decade.

The company struck agreements with German pharmaceutical company Stada in 2021 and again in 2023 to transfer rights to various products, further streamlining its portfolio toward higher-value therapeutics.

These measured steps have paved the way for the company’s current aggressive repositioning.

Reflecting broader leadership changes within the organization, Sanofi recently parted ways with longtime Chief Executive Officer Paul Hudson.

Belén Garijo, formerly a leader at fellow German pharmaceutical firm Merck KGaA, will assume the chief executive role on April 30, 2026.

Her appointment signals continuity in Sanofi’s innovation-focused strategy and marks a pivotal moment as the company enters its next chapter under new strategic direction.